GPR61 Inhibitors

Chemical inhibitors of GPR61 can effectively hinder the protein's function through various mechanisms impacting the G protein-coupled receptor (GPCR) signaling pathways. Pertussis Toxin is one such inhibitor that targets the Gi/o proteins, which are typically associated with GPR61. By irreversibly inactivating these G proteins, Pertussis Toxin disrupts the receptor's ability to inhibit adenylate cyclase, thereby functionally inhibiting GPR61's signaling. Similarly, GDP-β-S competes with GTP for binding to Gi/o proteins, consequently preventing GPR61 from activating its associated G proteins. As a result, the receptor's signaling cascade is functionally impaired. Clozapine, on the other hand, acts as an antagonist of GPR61 by directly blocking the receptor, which inhibits its ability to activate the intracellular signaling pathways.

In addition to these direct antagonists, other compounds indirectly inhibit GPR61 by targeting the downstream effectors of its signaling pathways. For instance, Suramin disrupts purinergic signaling that interacts with GPR61, thereby inhibiting the receptor's function. Go6976, a protein kinase C inhibitor, prevents the phosphorylation of proteins downstream from GPR61, leading to functional inhibition of the receptor's activity. U73122 inhibits phospholipase C, a key enzyme in the GPCR signaling cascade, which is essential for GPR61's function, by preventing the formation of second messengers. YM-254890 and BIM-46187 specifically inhibit Gq proteins, and since GPR61 can activate these proteins to transduce signals, their inhibition directly prevents the receptor from initiating downstream responses. NF449 targets the Gs alpha subunit, thereby blocking GPR61's ability to stimulate adenylate cyclase. Lastly, Cholera Toxin prevents GPR61's coupling to Gs proteins by catalyzing the ADP-ribosylation of the Gs alpha subunits, obstructing the receptor's signaling pathway.